Aeglea Biotherapeutics (AGLE) PT Lowered to $19 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Chad Messer lowered the price target on Aeglea Biotherapeutics (NASDAQ: AGLE) to $19.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
